Axiom Investors’s NeoGenomics NEO Stock Holding History

Axiom Investors’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-250,134	Closed	-$1.97M	–	155
2017 Q1	$1.97M	Sell	250,134 -35,591	-12%	-$290K	0.05%	122
2016 Q4	$2.45M	Buy	285,725 +141,853	+99%	+$1.22M	0.07%	116
2016 Q3	$1.18M	Sell	143,872 -159,283	-53%	-$1.34M	0.03%	111
2016 Q2	$2.44M	Buy	303,155 +27,954	+10%	+$224K	0.07%	97
2016 Q1	$1.85M	Buy	275,201 +129,951	+89%	+$855K	0.06%	112
2015 Q4	$1.14M	Buy	+145,250	New	+$1.06M	0.04%	120
2013 Q3	–	Sell	-230,300	Closed	-$917K	–	146
2013 Q2	$917K	Buy	+230,300	New	+$879K	0.03%	121

Other funds holding NEO

General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Axiom Investors's NEO Position: Q2 2017 in Review

Axiom Investors sold out of NeoGenomics (NEO) in Q2 2017, closing a stake of 250,134 shares — an estimated $1.97M sold.

Axiom Investors first reported a position in NEO in Q2 2013 and held it in 7 quarters. The position peaked at $2.45M in Q4 2016. 134 funds tracked by Wall St. Rank hold NEO as of Q2 2017.

Axiom Investors reported no remaining NeoGenomics position as of Q2 2017 after selling out during the quarter.
Axiom Investors sold 250,134 NeoGenomics shares in Q2 2017, an estimated $1.97M.
Axiom Investors first reported a position in NeoGenomics in Q2 2013 and held it in 7 quarters.
Axiom Investors's NeoGenomics position peaked at $2.45M in Q4 2016.
134 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2017.

Based on Axiom Investors's 13F filing for Q2 2017, filed 14 Aug 2017.